New drug may cut transfusions for MDS patients

NCT ID NCT05181592

Ongoing Disease control Sponsor: GWT-TUD GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called luspatercept in 70 adults with a low-risk form of MDS that causes anemia. The goal is to see if the drug can reduce the need for red blood cell transfusions. Participants receive the drug and are monitored for safety and effectiveness over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome myelodysplastic syndrome with ring sideroblasts Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Clinica di Ematologia Istituto oncologico della Svizzera Italiana

Bellinzona, 6500, Switzerland
Hospital General Universitario Gregorio Marañón

Madrid, 28009, Spain
Hospital Universitario Central de Asturias

Oviedo, 33011, Spain
Hospital Universitario y Politecnico La Fe de Valencia

Valencia, 46026, Spain
Hospital Vall d´Hebron

Barcelona, 08023, Spain
Institut Català d' Oncologia de Badalona

Badalona, 8916, Spain
Klinikum rechts der Isar

München, 81675, Germany
Medizinische Universität Innsbruck

Innsbruck, 6020, Austria
Medizinische Universität Wien

Vienna, 1090, Austria
University Hospital of Salamanca

Salamanca, 37007, Spain
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor

Bern, 3010, Switzerland
Universitätsklinikum Leipzig

Leipzig, 04103, Germany
Universitätsspital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.